Alpelisib 13C5,15N
| Product Name | Alpelisib 13C5,15N |
|---|---|
| Alternate Names | Alpelisib Stable Isotopes, Stable Isotopes of Alpelisib |
| CAT No. | CS-EK-02531 |
| CAS No. | 1217486-61-7 unlabeled |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | Not Available |
| Mol. For. | Not Available |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Alpelisib |
| Canonical Smiles | CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F |
| InchIKey | STUWGJZDJHPWGZ-LBPRGKRZSA-N |
| Inchl | InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1 |
| IUPAC | (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
[13C5,15N]-Alpelisib is a potent and selective inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, which is known to play a critical role in the regulation of cell growth, survival, and metabolism. The compound acts by blocking the activity of the PI3K enzyme, which is overactive in many types of cancer. This inhibition helps to prevent cancer cells from growing and dividing, thereby slowing or stopping the progression of the disease.
Chemically, [13C5,15N]-Alpelisib is a modified form of the drug Alpelisib, which contains five carbon-13 and fifteen nitrogen-15 isotopes. These isotopes provide a unique molecular fingerprint that can be used in research studies to track the behavior of the drug in the body. The modified version of the drug is used in pharmacokinetic studies to determine how the drug is absorbed, distributed, metabolized, and eliminated from the body.
[13C5,15N]-Alpelisib is typically administered orally, usually in the form of a tablet or capsule. The drug is currently undergoing clinical trials for the treatment of various types of cancers, including breast, ovarian, and prostate cancer. The use of [13C5,15N]-Alpelisib in these trials is aimed at improving the efficacy and safety of the drug, as well as gaining a better understanding of its pharmacokinetics and pharmacodynamics. Overall, [13C5,15N]-Alpelisib shows promise as a potential treatment for cancer, and further research is needed to fully explore its therapeutic potential.
Get an Instant Quote
Related Compounds
Alpelisib D3,15N | Alpelisib D7 | Alpelisib D3,15N2 | Alpelisib-d9 |